Bpr001-615

Preclinical

CCentre Hospitalier Universitaire de Nice

Bpr001-615 is one of 25 therapeutic programs targeting Colorectal Adenocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Colorectal AdenocarcinomaRecruiting

Colorectal AdenocarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

25 competitors in Colorectal Adenocarcinoma

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

—2

Levulan

Sun Pharmaceutical Industries, Inc.

Thalomid

Eloxatin

Taxol

Fudr

Gleevec

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 9

E-Mycin

AAzurity Pharmaceuticals

Glucophage

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Colorectal Adenocarcinoma

NCT07813884

Clinical

Trials by Indication[1]

Colorectal Adenocarcinoma1 trial

Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas

Recruiting·CCentre Hospitalier Universitaire de Nice·Preclinical·NCT07813884·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bpr001-615. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bpr001-615. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Centre Hospitalier Universitaire de Nice company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCentre Hospitalier Universitaire de Nice

Bpr001-615

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Colorectal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News